Feb 6, 2024 Awards Totaling $2.6 Million Support Exploration of Therapeutic Strategy for Adult and Pediatric T-cell Acute Lymphoblastic Leukemia


New Brunswick, N.J., February 6, 2024 – Daniel Herranz Benito, PhD, PharmD, resident researcher at Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only NCI-designated Comprehensive Cancer Center together with RWJBarnabas Health, and associate professor of pharmacology and pediatrics at Rutgers Robert Wood Johnson Medical School, has received a total of $2.6M to support his research on acute lymphoblastic leukemia (ALL), an aggressive type of leukemia that affects both children and adults. These awards include: Read more at cinj.com.